International Assets Investment Management LLC Sells 936,330 Shares of Zoetis Inc. (NYSE:ZTS)

International Assets Investment Management LLC decreased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 99.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,644 shares of the company's stock after selling 936,330 shares during the period. International Assets Investment Management LLC's holdings in Zoetis were worth $593,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ZTS. Sterneck Capital Management LLC boosted its stake in Zoetis by 12.1% during the fourth quarter. Sterneck Capital Management LLC now owns 2,224 shares of the company's stock worth $362,000 after buying an additional 240 shares in the last quarter. One Wealth Capital Management LLC acquired a new position in Zoetis in the fourth quarter worth about $864,000. Canandaigua National Bank & Trust Co. lifted its stake in Zoetis by 27.9% during the fourth quarter. Canandaigua National Bank & Trust Co. now owns 7,236 shares of the company's stock worth $1,179,000 after purchasing an additional 1,580 shares during the period. CWA Asset Management Group LLC boosted its holdings in Zoetis by 118.9% during the fourth quarter. CWA Asset Management Group LLC now owns 16,028 shares of the company's stock valued at $2,611,000 after purchasing an additional 8,706 shares in the last quarter. Finally, Pensionfund Sabic grew its stake in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after purchasing an additional 4,000 shares during the period. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 1.0 %

ZTS stock traded down $1.72 during trading on Friday, hitting $163.30. The company had a trading volume of 3,179,470 shares, compared to its average volume of 2,470,128. The stock has a market cap of $73.68 billion, a price-to-earnings ratio of 30.70, a PEG ratio of 2.91 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm has a 50-day moving average price of $171.71 and a 200-day moving average price of $180.23. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.36 earnings per share. As a group, analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. Zoetis's dividend payout ratio (DPR) is presently 37.59%.

Analysts Set New Price Targets

ZTS has been the topic of several recent analyst reports. Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price target on the stock. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a "neutral" rating and a $196.00 price target on the stock. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.